← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Fate Therapeutics FATE $219M	233	-17	-7%	$2.7B
27	27 Pacific Biosciences PACB $544M	228	-21	-8%	$1.03B
28	28 Ultragenyx Pharmaceutical RARE $1.45B	224	-16	-7%	$4.03B
29	29 Maravai LifeSciences MRVI $1.03B	216	-19	-8%	$3.73B
30	30 Adaptive Biotechnologies ADPT $3.88B	209	-13	-6%	$1.08B
31	31 Beam Therapeutics BEAM $2.41B	205	-35	-15%	$2.09B
32	32 Twist Bioscience TWST $8.77B	203	-9	-4%	$2.01B
33	33 Myriad Genetics MYGN $395M	198	-7	-3%	$1.46B
34	34 Veracyte VCYT $3.55B	193	-12	-6%	$1.52B
35	35 DELISTED SANGAMO THERAPEUTICS INC SGMO	188	-7	-4%	$371M
36	36 CareDx CDNA $3.31B	184	-29	-14%	$1.24B
37	ISEE 37 DELISTED IVERIC bio, Inc. Common Stock ISEE	184	+21	+13%	$1.15B
38	38 Vericel Corp VCEL $2.06B	183	-15	-8%	$1.34B
39	39 PTC Therapeutics PTCT $4.96B	181	-4	-2%	$2.97B
40	40 DELISTED 23andMe Holding Co ME	179	+18	+11%	$258M
41	41 Precigen PGEN $2.38B	169	-4	-2%	$182M
42	42 uniQure QURE $1.53B	168	-6	-3%	$756M
43	43 Regenxbio RGNX $459M	165	-23	-12%	$896M
44	44 BridgeBio Pharma BBIO $12.8B	164	-14	-8%	$1.28B
45	NSTG 45 DELISTED NanoString Technologies, Inc. NSTG	163	-15	-8%	$621M
46	46 Allogene Therapeutics ALLO $449M	161	-19	-11%	$1.15B
47	47 DELISTED BioLife Solutions BLFS	159	-5	-3%	$509M
48	48 DELISTED bluebird bio BLUE	150	-24	-14%	$228M
49	49 Legend Biotech LEGN $3.62B	150	+9	+6%	$2.9B
50	50 Rocket Pharmaceuticals RCKT $249M	147	-2	-1%	$892M